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Inhibition of Histone Deacetylation Promotes
Abnormal Epidermal Differentiation and Specifically
Suppresses the Expression of the Late Differentiation
Marker Profilaggrin
Nelli G. Markova1, Nevena Karaman-Jurukovska1, Adriana Pinkas-Sarafova1, Liuben N. Marekov2 and
Marcia Simon1
Reversible protein acetylation modulates higher-order chromatin structure and transcription activity of the
genome. The reversible acetylation is executed by the intrinsic acetylase and deacetylase activities of co-
regulators associated with the regulatory regions. Compounds capable of inhibiting deacetylase activity are a
powerful tool for dissecting the role of protein acetylation in gene function. The ability of the deacetylase
inhibitors to preferentially affect the homeostasis of transformed cells has also prompted studies for their
clinical application. We present evidence that deacetylase inhibition with trichostatin A (TSA) affects the normal
epidermal tissue architecture and pattern of expression by a mechanism(s) that does not correlate directly with
the hyperacetylated histone status. While promoting abnormal differentiation, TSA specifically represses
transcription initiation of the differentiation marker profilaggrin. Multiple factors, among which we have
identified decreased Sp1 binding, a local decrease in acetylation activity, and enhanced synthesis and
recruitment of a repressor histone demethylase, alter the chromatin configuration over the promoter, ultimately
blocking its activation by c-jun. As compromised profilaggrin production leads to epidermal and consequently
allergic disorders, our findings emphasize the need for a detailed investigation of the role deacetylase inhibitors
may play in the maintenance of epidermal homeostasis in order to optimize their clinical applicability.
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INTRODUCTION
The eukaryotic chromatin is generally divided into two
cytologically and functionally distinct fractions: the tightly
compacted heterochromatin associated with transcriptionally
silent genome regions and the less condensed euchromatin,
which tends to be transcriptionally permissive (Wolffe and
Kurumizaka, 1998). Among the factors that mediate chroma-
tin transition is the deposition of covalent post-translational
modifications on histone and non-histone chromatin pro-
teins. The specific protein marks and the regulatory proteins
that make them, remove them or act upon their presence
epigenetically determine the transcription activity and there-
by represent key regulators of cellular homeostasis (e.g., see
Ura et al., 1997; Workman and Kingston, 1998; Spencer and
Davie, 1999; Hake et al., 2004; Rosenfeld et al., 2006).
The reversible acetylation is one of the best-studied post-
translational modifications modulating gene expression. Acet-
ylation is generally correlated with active transcription, whereas
deacetylation is more often linked to transcriptional repression
(Ura et al., 1997; Workman and Kingston, 1998). The pattern of
acetylation is controlled by the opposing activities of histone
acetylases and deacetylases (HDACs) (Kuo and Allis, 1998). As
the actively transcribed chromatin associates with dynamically
acetylated proteins, the recruitment of both histone acetylases
and HDACs to the regulatory regions through DNA-binding
transcription factors serves to switch on and off gene transcrip-
tion in response to cellular needs and extracellular cues (see
Rosenfeld et al., 2006). However, mistargeting or perturbed
balance between acetylating and deacetylating activities leads
to aberrant expression of key regulators of cell growth,
differentiation, and apoptosis and is often associated with
malignancy (see Marks et al., 2004; Peart et al., 2005).
The elucidation of the role of protein (de)acetylation in
norm and disease has been facilitated by the discovery of
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chemically diverse agents capable of inhibiting the protein
deacetylases. In transformed cells and solid tumors and to a
lesser extent in normal cells HDAC inhibitors (HDACi)
induce cell growth and cell cycle arrest, differentiation and,
in certain cases, apoptosis (see Yoshida et al., 2003; Marks
et al., 2004; Dokmanovic and Marks, 2005; Peart et al.,
2005). The ability of HDACi to preferentially affect the
homeostasis of the transformed cells has prompted studies of
their clinical application as anticancer agents either alone or
in combination with other chemotherapeutics (see Johnstone
and Licht, 2003; Marks et al., 2004; Garcia-Manero and Issa,
2005). Pretreatment of cancer cells with HDACi appears also
to enhance their sensitivity to ionizing radiation (Zhang et al.,
2004, see Karagiannis and El-Osta, 2006). Therefore, there is
an ongoing effort to design HDACi specifically optimized for
their radiation sensitizing properties (Jung et al., 2005). The
therapeutic benefit of the radiotherapy, however, is limited
by acute and long-term side effects that are especially
pronounced in skin, which is always affected by external
radiotherapy. Unexpectedly, it was recently observed that
HDACi might also serve as radioprotectors of normal rat skin
(Chung et al., 2004). These findings open the possibility of
using HDACi to not only enhance the anticancer potential of
the radiotherapy but also to selectively reduce skin morbidity.
Earlier studies indicate that when the activity of HDACs is
inhibited, cultures of both transformed and normal human
epidermal keratinocytes cease to proliferate and rapidly
undergo differentiation (Schmidt et al., 1989; Staiano-Coico
et al., 1990a; Saunders et al., 1999; Brinkmann et al., 2001).
Whether inhibition of protein deacetylation affects the
homeostasis of the normal epidermal tissue, however, is
unknown. We initiated the present studies with the goal to (i)
examine the effect of inhibition of protein deacetylation on
epidermal structure and (ii) determine whether HDACi can
coordinately regulate the transcription of epidermal genes
expressed during distinct stages of epidermal differentiation.
We observed that inhibition of protein deacetylation in organ
epidermal cultures with the classic HDACi trichostatin A
(TSA) markedly affects the epidermal architecture and the
expression pattern of epidermal marker genes by a mechan-
ism(s) that does not correlate directly with their status of
histone acetylation. Of the three genes residing in the
Epidermal Differentiation Complex (EDC) (Mischke, 1998),
TSA induces involucrin, has little effect on loricrin but
specifically inhibits the initiation of profilaggrin transcription.
The TSA-dependent repression of the endogenous profilag-
grin transcription depends on protein synthesis and can be
reproduced on minichromosomes carrying a reporter gene
controlled by the profilaggrin promoter. Although it remains
associated with acetylated histones, decreased levels of
endogenous Sp1 binding, a local decrease in the acetylation
activity, and enhanced synthesis and recruitment of a
repressor histone H3 demethylating enzyme most likely
contribute to altering the chromatin configuration over the
promoter, thereby blocking its activation by c-jun.
As aberrant profilaggrin/filaggrin production and function
leads to epidermal and consequently allergic disorders
(Palmer et al., 2006; Smith et al., 2006), our findings
emphasize the need for a detailed investigation of the
mechanisms through which HDACi impact the epidermal
homeostasis in order to optimize their clinical applicability.
RESULTS
Inhibition of protein deacetylation promotes abnormal
epidermal differentiation but does not elicit a coordinated
response from epidermal marker genes
To assess the role of protein acetylation in the maintenance of
normal epidermal architecture, we incubated organ cultures
of human foreskin for 48 hours in keratinocyte growth
medium in the absence or presence of 100 nM TSA – an
inhibitor of class I/II protein deacetylases (Yoshida et al.,
1990). As revealed by the hematoxylin and eosin staining of
the frozen sections, deacetylase inhibition led to drastic
changes in the epidermal architecture (Figure 1a, e). All
epidermal layers appeared affected. The basal layer lost its
columnar organization and showed a reduced cellularity.
Fewer spinous layers were observed. There was an increase
in the thickness of the cornified layers.
Similarly, after 2 days in TSA-containing medium, both
subconfluent and confluent submerged cultures of normal
human epidermal keratinocytes (NHEK) contained many
enlarged cells with a flattened appearance and uneven
periphery (data not shown). On the protein level, in the
TSA-treated NHEK we observed decreased expression of the
proliferation marker c-myc and induction of the differentia-
tion marker cyclin-dependent kinase inhibitor p21WAF1/CIP1;
the expression of cyclin D was not affected (Figure 1i,
compare lanes 1 and 2). Both control (Figure 1i, lane 3) and
NHEK treated with 100 nM (lane 4) and 200 nM TSA (lane 5)
showed equal amounts of the poly(ADP-ribose) polymerase 1
– a specific target of chemically induced apoptosis-mediated
proteolysis (Kaufmann et al., 1993). Significantly, incubation
for 48 hours even with 200 nM TSA did not increase the
intensity of the signature 85 kDa apoptotic fragment (arrow).
Expanding the published data discussed above (Schmidt
et al., 1989; Staiano-Coico et al., 1990a; Saunders et al.,
1999; Brinkmann et al., 2001), these findings suggested that
without inducing apoptosis TSA was blocking the prolifera-
tion and concomitantly accelerating the terminal differentia-
tion of the epidermal keratinocytes. Therefore, we
hypothesized that TSA may coordinately regulate the expres-
sion of the epidermal markers genes and/or gene clusters
during the keratinocyte differentiation. We focused on the
involucrin, loricrin, and profilaggrin genes. All three reside in
the EDC on 1q21 (Mischke, 1998), encode proteins expressed
in the later stages of epidermal differentiation and by both
criteria were expected to be upregulated by TSA. As seen in
Figure 1, treatment of the organ cultures with 100 nM TSA for
48 hours appeared to increase the amount of involucrin (b, f)
and to restore the upper spinous layer specificity of
expression, which is routinely lost in organ cultures (Simon
M., unpublished results). The expression of loricrin remained
practically unchanged (c, g), whereas the amount of profilag-
grin was markedly reduced (d, h). These trends were
confirmed on both RNA and protein level in epidermal
preparations derived from control and TSA-treated foreskin
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organ cultures (Figure 1j) and were also reproduced in NHEK
(Figure 1k). TSA treatment of foreskins and confluent NHEK
increased involucrin mRNA (top) and protein (bottom)
production (Figure 1j, k, lanes 5, 6). It did not affect the
loricrin mRNA levels (Figures 1j, k, lanes 7, 8, top). The
amount of the protein did not change in the foreskin
epidermis (Figure 1j, lanes 7, 8, bottom) and in NHEK
remained barely detectable (Figure 1k, lanes 7, 8, bottom).
Profilaggrin mRNA and protein levels were only 20–30% of
the untreated controls (Figures 1j and k, lanes 9, 10).
Apparently, the TSA-mediated profilaggrin suppression was
not significantly influenced by differentiation, as it was
observed with NHEK grown with 3T3 feeder cells in serum-
containing medium, as well as in NHEK grown in serum-free
medium at low (0.05 mM) and high (1.2 mM) calcium
concentrations (data not shown).
TSA modulates the expression of the late differentiation markers
at the level of transcription initiation
Establishment of a permissive chromatin configuration
through histone acetylation is a prerequisite for transcrip-
tional activation (Ura et al., 1997). As chromatin
immunoprecipitation with a pan-acetyl antibody revealed,
in NHEK, where they are normally transcribed, profilaggrin,
loricrin, and involucrin genes (Figure 2a) are associated
predominantly with the acetylated, active chromatin. In
contrast, in the control dermal fibroblasts the epidermal-
specific sequences (shown for profilaggrin) were detected in
the hypoacetylated chromatin fraction, which was not
immunoprecipitated with the pan-acetyl antibody. In both
cell types the gene for the housekeeping glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), used as a control, was
found predominantly within the acetylated chromatin. Sig-
nificantly, treatment with TSA, which caused accumulation
of acetylated histones in both NHEK and dermal fibroblasts
(Figure 2b), did not lead to redistribution of the profilaggrin
gene between the two chromatin fractions in either cell type.
To determine whether the TSA-mediated alterations
occurred at the level of transcription initiation or resulted
from post-initiation events, we isolated nuclei from control
and TSA-treated NHEK, incubated them with [a-32P]GTP and
hybridized the labeled nascent transcripts to immobilized
profilaggrin, involucrin, loricrin, or GAPDH cDNA se-
quences. As seen in Figure 2c, the nuclei isolated from
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Figure 1. Effect of protein deacetylase inhibition in organ and submerged epidermal cultures. (a) Hematoxylin and eosin (a, e, bar¼ 30 mm) and (b–h,
bar¼ 12 mm) indirect immunofluorescent staining of frozen sections prepared from control and TSA-treated organ cultures of foreskin epidermis. The green
color shows the signals for involucrin (Inv), loricrin (Lori), and profilaggrin (PF) detected after incubation with the respective antibodies and Alexafluor 488-
conjugated secondary antibodies. The nuclei were visualized with DAPI. (i) The expression of the designated proteins in total NHEK extracts in the absence
(lanes 1, 3), 100 nM (lanes 2, 4) and 200 nM (lane 5) TSA. The arrow points to the 85 kDa polypeptide generated upon apoptotic-specific cleavage of poly(ADP-
ribose) polymerase 1. (j and k) Analyses of RNA and protein levels of the designated epidermal markers in control () and 100 nM TSA-treated (þ ) (j) foreskin
organ and (k) submerged NHEK cultures. The arrowhead points to the mature filaggrin peptide discernible only in the foreskin preparations. Lanes 1 and 2 are
photographs of ethidium bromide stained total RNA gels typically used in the analyses; lanes 3 and 4 represent GelCode Blue stained gels of the total proteins
extracted after the removal of the RNA. The RNA signals (top rows) are in reference to 18S rRNA (middle rows).
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TSA-treated NHEK initiated markedly less profilaggrin but
more involucrin transcripts compared to the untreated
controls; the loricrin and the control GAPDH transcripts
were practically unaffected. Thus, while not affecting loricrin,
inhibition of protein deacetylation exerts its opposing effects
on profilaggrin and involucrin production already at the level
of transcription initiation.
TSA-mediated profilaggrin repression is sensitive to inhibition of
protein synthesis
Treatment of NHEK with 100 nM TSA for up to 24 hours
revealed that the decrease in profilaggrin mRNA levels
occurred between 6 and 9 hours of incubation and was
delayed compared to the effect on c-myc mRNA (Figure 2d).
It was observed several hours after a hyperacetylated histone
status was established (Figure 2e). Therefore, it was unlikely
that the prevailing mechanism of the TSA-mediated repres-
sion involved immediate chromatin remodeling or modifying
the activity of an already present transcriptional regulator(s)
following hyperacetylation of the histones associated with the
profilaggrin gene. Rather, the data suggested the synthesis of
a factor in trans, which then interfered with the initiation of
profilaggrin transcription. Indeed, inhibitors of both transla-
tion and transcription were able to reverse the TSA effect.
When NHEK were treated with TSA for 24 hours and
subsequently for 9 hours with either cycloheximide or
actinomycin D in the presence of TSA (Figure 2f), the level
of profilaggrin mRNA in the presence of TSA was higher than
in its absence. Moreover, nuclei isolated from NHEK treated
with TSA for 24 hours and then for additional 9 hours with
TSA and cycloheximide, synthesized only about 3-fold less
profilaggrin transcripts, compared to the cycloheximide-
untreated TSA-treated controls (Figure 2g, compare lanes 4
and 2). In comparison, in nuclei isolated from cells that had
not been treated with TSA but subjected to treatment with
cycloheximide, profilaggrin transcription initiation was in-
hibited more than 10-fold (compare lanes 3 and 1). TSA
treatment did not alter the amount of nascent GAPDH
transcripts. As previously reported (Nirunsuksiri et al., 1998),
the initiation of GAPDH transcription was not sensitive to
cycloheximide either.
The inhibitory effect of TSA is transmitted through specific
regulatory elements
To explore whether the TSA-dependent inhibition of profilag-
grin transcription affects the basal transcription machinery
exclusively or involves additional regulatory elements up-
stream of the transcription initiation site, we transfected
NHEK with chloramphenicol acetyl transferase (CAT) repor-
ter plasmids controlled by decreasing lengths of the
profilaggrin 50-region 1532/þ9 (Jang et al., 1996). As seen
in Figure 3a 100 nM TSA repressed the activity of all
profilaggrin constructs. Under the same conditions the
activity of CAT reporters regulated by involucrin (2473/
þ 9), loricrin (154/þ 9), or keratin K5 (705/þ6) promoter
regions remained unaltered. The minimal region of the
profilaggrin promoter, which retained full responsiveness to
TSA in a concentration- (Figure 3b) and time- (Figure 3c)
dependent manner, extended 116 bp upstream of the
transcription initiation site. Although we cannot exclude
involvement of the basal transcription apparatus, the fact that
constructs 59/þ 9-CAT and 41/þ 9-CAT gradually lost
responsiveness to TSA indicated that upstream regulatory
elements within the proximal promoter region were required
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Figure 2. TSA represses profilaggrin transcription initiation. (a) Chromatin immunoprecipitation analysis of profilaggrin (PF), loricrin (Lori), involucrin (Inv), and
GAPDH DNA in chromatin isolated from control () and TSA-treated (þ ) NHEK (KC) and dermal fibroblasts (DF). The crosslinked chromatin was
immunoprecipitated with anti-pan-acetyl antibody or with nonspecific IgGs (NIS) and the designated DNA sequences in the bound and unbound fractions were
detected by PCR. (b) Acetylated histone H3 detected by Western blotting in the nuclear extracts of control () and TSA-treated (þ ) NHEK and dermal fibroblasts.
(c) Nascent profilaggrin, loricrin, involucrin and GAPDH transcripts synthesized in nuclei isolated from control () and TSA-treated (þ ) NHEK. (d) Levels of
profilaggrin, c-myc, and 18S rRNA detected by RNase protection in NHEK treated with TSA for the indicated times. (e) Total histones were obtained from the
same cells after RNA isolation and the level of acetylation detected with anti-pan-acetyl antibody. The GelCode staining of the protein gel is shown as a
reference. (f) Effect of cycloheximide (CHX) and actinomycin D (ActD) on the TSA-mediated regulation of profilaggrin and GAPDH mRNA levels in NHEK,
detected by RT-PCR. (g) Nascent profilaggrin and GAPDH transcripts synthesized in nuclei isolated from control (lane 1), TSA (lanes 2, 4) and cycloheximide
(lanes 3, 4) treated NHEK, detected after RNase H protection. Lane M shows the mobility of the denatured 90, 76, and 67 bp fragments of the pBR322/MspI DNA
marker (New England BioLabs, Beverly, MA).
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for full suppression. In contrast, the regulatory elements
responsible for the enhanced involucrin transcription were
apparently not present or functional within the respective
reporter.
Mutation scanning and functional analyses (Jang et al.,
1996, 2000; Andreoli et al., 1997; Markova et al., 2006 and
unpublished results (Markova N.G., Jang S-I, Steinert P.M.,
unpublished results)) had previously identified proximal
motifs indispensable for full profilaggrin promoter activity
(Figure 3d). After transfection into NHEK, treatment with
100 nM TSA for 48 hours reduced the expression of the wild
type 116/þ9-CAT and all but two of the indicated mutant
constructs 2.5 to 3-fold. The exceptions were the reporters
S-100 and S-50, which harbored mutations in the GT repeats
at positions 101 to 96 and 57 to 45, respectively. The
S-100 and S-50 mutant constructs retained only 30% of the
wild-type activity but were not sensitive to TSA (Figure 3e).
Mutation of the S-100 and S-50 motifs in the context of the
entire 50-region up to 1532 elicited the same response (data
not shown), thus confirming their essential role in the
transmission of the TSA effect. Similar to its impact on the
endogenous profilaggrin expression, the TSA mediated
downregulation of profilaggrin promoter activity in the
minichromosomes was differentiation independent (data not
shown). Notably however, it was keratinocyte specific. In
HeLa cells, which do not transcribe the profilaggrin gene
but in which the profilaggrin promoter shows a weak
activity (Jang et al., 1996), TSA induced at least 2-fold higher
reporter expression, which depended on an intact S-50 motif
(Figure 3f).
HDAC inhibition alters the DNA/protein interactions over the
promoter
Comparison between DNase I digestion profiles of profilag-
grin promoter DNA unspecifically associated with BSA
(Figure 4a, lanes 1, 2) or specifically bound to nuclear
proteins isolated from control (lanes 3, 4) and TSA-treated
(lanes 5, 6) NHEK revealed that deacetylase inhibition did not
grossly change the pattern of protection. Under both
conditions the region encompassing nucleotides 30 to
99 was protected from DNase I digestion and showed
DNase I hypersensitivity at the nucleotides marked with
asterisks. Largely, this profile was determined by simulta-
neous binding of Sp1 and c-jun (compare lanes 1–6, 9 with
lanes 10–12). However, with the TSA-treated samples we
detected two new DNase I hypersensitive sites – at position
52 and 96 (arrowheads), which resided within the S-50
and S-100 motifs, respectively. The hypersensitivity at
position 95 (marked with a dot) was no longer discernible.
The TSA-specific DNase I digestion profile depended on
intact S-50 and S-100. Mutation of S-50 abolished the
footprint between 30 and 60, as well as the hypersensi-
tivity at positions 35 and 55; the TSA-specific hypersensi-
tivity at position 52 was no longer present (compare lanes
5–7). Similarly, mutation of S-100 reduced the protection
between 90 and 99 and nucleotides 95 and 96 were
no longer preferred targets for the DNase I attack (compare
lanes 5, 6, and 8). These notable distinctions were indicative
of changes in the chromatin structure.
The bandshift profiles presented in Figure 4b, c indicated
that the predominant interactions (complex A) of S-50 and S-
100 involve transcription factors Sp1 and Sp3. In addition,
both motifs bind weakly to the Notch effector RBP-Jk
(complex B). Compared to the untreated controls, the binding
profiles of S-50 and S-100 with nuclear extracts of TSA-
treated NHEK consistently showed a 40–50% decrease in the
intensity of complex A, whereas the intensity of complex B
remained unchanged (Figure 4d, lanes 1–4). The decrease in
the Sp1/Sp3 binding was not caused by cytotoxicity of TSA,
because the same extracts showed higher intensity of the
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Figure 3. The effect of TSA is transmitted through specific regulatory
sequences. (a) Relative CAT activity detected in extracts of control (black bars)
NHEK transfected with reporters regulated by decreasing lengths of the
profilaggrin 50-region between 1532 and þ 9, involucrin region 2473/þ 9,
loricrin region 154/þ9, and K5 region 705/þ 6 and in NHEK treated with
100 nM TSA for 48 hours (striped bars). (b and c) The TSA dose and time
responses, respectively of reporter 116/þ 9-CAT. (d) Schematic presentation
of the profilaggrin proximal promoter and the designated regulatory motifs.
The arrow marks the transcription initiation site. (e, f) Relative CAT activity of
the wild-type and the designated mutant reporters in control (black bars) and
TSA-treated (striped bars) (e) NHEK and (f) HeLa cells. The activity of each of
the wild type reporters in the control cells is set at 100%. The data
(mean7SD) are an average of at least five experiments, each in duplicate.
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activator protein 1 (AP1)-containing complexes (lanes 5, 6)
(Jang et al., 1996) and incubation of NHEK with 200 nM TSA
for 48 hours did not induce apoptotic-specific cleavage of the
poly(ADP-ribose) polymerase 1 enzyme (Figure 1i). Thus, the
observed intensities of the bandshifts likely reflected the
altered amounts of the respective transcription factors in
response to TSA (Figure 4e). Surprisingly, therefore, in the
presence of nuclear extracts from TSA-treated NHEK,
oligonucleotides AP1/S-50 (Figure 4d) and AP1/S-100 (data
not shown), which encompassed AP1 and S-50 or S-100
motifs, respectively, assembled not only fewer Sp1-specific
complexes A, but also fewer AP1-containing complexes C;
no change in the intensity of complex B was detected
(compare lane 7, 8). As none of the AP1 proteins known to
interact with the profilaggrin AP1 motif (Jang et al., 1996)
were found downregulated by TSA (Figure 4e), these results
indicated that, through interactions over S-50 and S-100,
treatment with TSA could alter the protein occupancy at the
AP1 motif.
Forced expression of Sp1 alleviates the TSA-mediated
repression and releases the block on c-jun transactivation
To explore the functional relevance of the above observa-
tions, we co-transfected wild type and mutant profilaggrin
354/þ 9-CAT reporters in NHEK together with Sp1 or/and
c-jun-loaded expression vectors (Figure 5).
Sp1 enhanced the expression of the wild-type (a) and the
AP1-mutant (e) reporters in a dose-dependent manner in both
TSA-untreated and treated NHEK. Moreover, forcing higher
levels of Sp1 into the cells interfered with the repressive effect
of TSA at both 100 and 200 nM concentrations (b). The S-100
(c) and S-50 (d) mutant reporters remained Sp1-responsive,
probably because interactions of Sp1 at the remaining intact
S-motifs were still able to activate the promoter, albeit to a
lesser extent and at higher Sp1 concentrations (see also
Markova et al., 2006). As TSA only marginally repressed the
activity of S-100 and S-50, it is unclear to what extent Sp1
contributed to the alleviation of the TSA effect for these
reporters. Underscoring the cell type specificity, forced
expression of Sp1 did not increase the reporter expression
in the control HeLa cells but prevented the TSA-mediated
activation in S-100 and S-50-dependent mode (data not
shown).
In contrast to Sp1, the dose-dependent activation of the
wild type promoter enacted by forced expression of c-jun
(Figure 5f) in the control NHEK (black bars) was completely
prevented by the deacetylase inhibitor (striped bars). The
inability of c-jun to transactivate the promoter in the presence
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proximal promoter sequences in the presence of BSA (lanes 1, 2, and 9), NHEK nuclear proteins (lanes 3–8), recombinant Sp1 (lane 10), c-jun (lane 11), or Sp1
and c-jun (lane 12). The black triangles show digestion with decreasing amounts of DNase I. The long double-headed arrows show the protected regions. The
stars mark the DNase I hypersensitive sites common for both control () and TSA-treated (þ ) NHEK samples, the arrowheads point to the hypersensitive sites
unique for the TSA-treated preparations, the dot marks the hypersensitive site evident only upon interactions of the promoter with nuclear proteins derived from
control NHEK. The GA lane represents the pyridine residues profile after Maxam and Gilbert chemical sequencing of the promoter region. The numbers on the
left show the positions of the nucleotides relative to profilaggrin transcription initiation site. (b–d) Bandshift analysis of the indicated oligonucleotides after
interactions with NHEK nuclear proteins. A, B, C represent the specifically retarded bands, the stars point to nonspecific complexes; the oligonucleotide
competitors and the interfering antibodies are shown above the lanes. The positions of the supershifts (in italics) obtained upon incubation with the indicated
antibodies are marked with arrowheads. (e) Western blot analyses with the indicated antibodies of the nuclear extracts (shown on the left) derived from control
() and TSA-treated (þ ) NHEK.
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of TSA was consistent with the lack of a parallel between
the TSA-induced levels of c-jun in the NHEK extracts
(Figure 4e) and its binding efficiency over AP1/S-50
oligonucleotide (Figure 4d). Notably, the S-100 and S-50
mutations, which did not interfere with c-jun transactivation
in the control cells, were able to release the TSA-imposed
block (Figure 5g, h).
Simultaneous co-transfection of Sp1 and c-jun led to a
dose-dependent synergistic activation of the wild-type
promoter in both TSA-treated and control NHEK, indicating
that increasing the amount of Sp1 was sufficient to release the
TSA-mediated block in c-jun transactivation. The synergism
was evident with both S-100 (data not shown) and S-50
mutants and was lost only upon mutation of the AP1
recognition motif (Figure 5i).
About 30–50% of the complexes A assembled over S-100
and S-50 (Figure 4b, c) contained Sp3 – a transcription factor
of the Sp1 family often found to competitively antagonize Sp1
activation of natural promoters in various cell types,
including epidermal keratinocytes (Jang and Steinert, 2002).
However, as Figure 5j shows, in the absence of TSA (black
bars), forced expression of Sp3 activated the wild-type
reporter just like Sp1. Rather than compete with each other,
Sp1 and Sp3 appeared to additively upregulate the activity.
When Sp3 was substituted with a mutant lacking DNA-
binding domain, the transactivation was comparable to that
exerted by the respective amount of Sp1 alone. When the
transfected NHEK were grown in 200 nM TSA (shaded bars),
Sp3 was less efficient than Sp1 in activating the reporters.
This result was consistent with the reported sensitivity of Sp3
activator function to acetylation within its inhibitory domain
(Braun et al., 2001). Nevertheless, Sp3 was still able to
counteract the silencing caused by TSA. Combined with the
lower levels of nuclear Sp3 in the TSA-treated NHEK (Figure
4e), these results argue against Sp3 being a major factor
whose action Sp1 counteracts in transmitting the TSA effect.
Combined with the lack of response in levels and binding
activity (Figures 4b–e), our preliminary data (not shown)
indicate that significant involvement of RBP-Jk in the
repression mechanism exposed by the inhibition of protein
deacetylation is also unlikely.
Deacetylase inhibition affects the recruitment of Sp1 and c-jun
and decreases the acetylation activity over profilaggrin
promoter in an S-motif dependent mode
We explored the extent to which TSA treatment affected the
recruitment of Sp1 and c-jun over the promoter by incubating
streptavidin magnetic beads coated with biotinylated profi-
laggrin fragment 147/þ 9 with nuclear extracts from TSA-
treated and control NHEK. Invariably, the input (52.6713.9),
the bound (54.1715.4) and the unbound (52.7711.4)
material from the TSA-treated NHEK contained about 50%
less Sp1 protein, compared to the untreated controls (Figure
6a). Inclusion of recombinant Sp1 in the binding reactions
increased the amount of the recruited Sp1 and eliminated the
difference between the TSA-treated and untreated samples
(Figure 6a, lanes 11, 12), whereas inclusion of recombinant
c-jun could not apparently affect the recruitment of Sp1
(lanes 13, 14). The retention of Sp1 on the promoter-coupled
beads was competed by S-50 (lanes 7, 8), S-100 (data not
shown) and consensus Sp1 (lanes 19, 20) but was not
sensitive to competition with either OctA (lanes 15, 16) or
AP1 (lanes 17, 18) oligomers. Thus, under both conditions the
recruitment of Sp1 over the promoter reflected the amount of
Sp1 protein in the respective nuclear extracts and was not
influenced by the AP1 interactions.
Despite the induction of c-jun expression, the bound
fractions from the TSA-treated NHEK retained 1.5 to 2-fold
less c-jun compared to the untreated controls (compare lanes
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Figure 5. Inhibition of protein deacetylation interferes with c-jun activation
of profilaggrin promoter. Relative activities of wild-type and mutant
profilaggrin CAT reporters in control (black bars) and TSA-treated (striped and
shaded bars) NHEK co-transfected with (a–e) 0.2 or 0.5 mg of Sp1, (f–h) c-jun,
or both (i) Sp1 and c-jun expression vectors. The cells in (b) were co-
transfected with 0.5 mg Sp1 and treated with 100 nM (striped bars) or 200 nM
(shaded bars) TSA. (j) The reporter 354/þ 9 was co-transfected with 0.2 or
0.5mg Sp1 and Sp3, Sp1þ Sp3, or Sp1þ Sp3-mutant expression vectors and
treated with 200 nM TSA (shaded bars). For each set, the activity of CAT is
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duplicate.
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4 and 3). Preincubation of both extracts with excess of AP1
oligonucleotides prevented efficient recruitment of c-jun but
had no effect on the recruitment of Sp1 (lanes 17, 18). In
contrast, not only was more c-jun recruited upon preincuba-
tion with Sp1-binding oligonucleotides (lanes 7, 8, 19, and
20), but also there was no longer a difference between
the TSA-treated and untreated samples. (Preincubation
with control OctA oligomers had little effect on the
recruitment of c-jun (lanes 15, 16)). Significantly, inclusion
of recombinant c-jun in the binding reactions increased
the amount deposited over the promoter by the control but
not by the TSAþ extract (lanes 13, 14). Inclusion of
recombinant Sp1, on the other hand, markedly increased
c-jun binding in both types of extracts (lanes 11, 12). Thus, in
contrast to Sp1, the recruitment of c-jun was not proportional
to the amount of the protein in the nuclear extracts.
Apparently, it was modulated by the relative amounts of
Sp1 and another, negative regulator(s) recruited through S-50
(and S-100).
Often, the activity of the DNA-bound transcription factors
is modulated by co-regulatory complexes with intrinsic
acetylase and/or deacetylase activities (see Rosenfeld et al.,
2006). To assess whether the TSA treatment affected the
acetylation activity over the promoter, we subjected the
input, bound and unbound samples to an in vitro acetylation
assay. The amount of the histones, acetylated under the
designated experimental conditions, is shown in Figure 6b.
The TSA treatment had no effect on the acetylation activity of
the input extracts per se and did not markedly change the
acetylation activity that remained in the unbound fractions
(compare black and striped bars). However, the acetylation
activity deposited by the TSAþ extract over the promoter was
almost 4-fold less than the untreated bound control. Although
the overall acetylation activity in the bound fractions was
lower, we observed a similar ratio between the TSA-untreated
and treated bound samples when the magnetic beads were
coated not with the entire proximal promoter region but only
with a biotinylated S-50 oligonucleotide (Figure 6b, compare
black and striped bars for (Bound) and (S-Bound). Our
previous work has documented that c-jun is essential for
recruitment and/or activation of acetylating enzymes at the
profilaggrin promoter (Markova et al., 2006). Accordingly,
preincubations of the nuclear extracts with AP1 oligomers
decreased the overall acetylation activity, especially in the
TSA-treated samples. However, increasing the amount of
c-jun available for binding by preincubation of the nuclear
extracts with recombinant c-jun, whereas increasing the
acetylation activity in the control bound fraction by 2-fold, in
fact enhanced the TSA effect.
In contrast, preincubation of the extracts with excess of
S-50 oligomers or with recombinant Sp1 eliminated the
difference between the TSA-treated and untreated bound
fractions and resulted in acetylation activities which were
about 2-fold higher than the activity of the control bound
fraction. There was no change in the acetylation activity in
the respective unbound fractions (data not shown).
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Because the suppression of profilaggrin transcription
initiation by TSA was sensitive to cycloheximide, we
hypothesized that TSA promotes the synthesis of a repres-
sor(s), whose recruitment over the promoter via S-50 (and
S-100) modifies in turn the interactions of Sp1 and c-jun and
causes a decrease in the acetylation activity. If we were
correct, we might expect that providing this factor(s) to the
binding reactions of the TSA extract would lower the
acetylation activity of the bound fraction. To test this, we
incubated the promoter-coated beads with a nuclear extract
from NHEK that had not been treated with TSA and to which
we added either the TSA (Rb) or the TSA
þ (Tb)-bound
fractions. Whereas combining the control extract with the Rb
fraction resulted in 3-fold more acetylated histones, the
addition of the Tb fraction drastically decreased the acetyla-
tion activity (Figure 6b, the black bars marked with asterisks).
When we repeated the experiment this time adding the
bound fractions eluted after preincubation of the extracts with
S-50 oligomers (RS50b and T
S50
b ), the T
S50
b fraction was no
longer able to diminish the acetylation activity of the bound
fraction from the control NHEK (Figure 6b, shaded bars
marked with asterisks).
Under the experimental conditions, the observed acetyla-
tion activity reflected mostly the presence of acetylating
enzymes, as class I/II deacetylases were inhibited by sodium
butyrate and class III enzymes were inactive in the absence of
the co-substrate NAD. Therefore, we assessed the protein
fractions described above for the presence of three co-
regulators, namely CBP, p300, and pCAF, with proven acetyl
transferase activity (Nakatani, 2001) and known to associate
with and acetylate Sp1 in response to TSA (Huang et al.,
2005). We found that both CBP and p300 were recruited over
the promoter (Figure 6c), whereas pCAF was practically
undetectable (data not shown). Without much affecting their
levels within the cells, treatment with TSA reduced the
retention over the promoter of both acetylases in a mode
dependent on S-50.
TSA treatment enhances the recruitment of the transcriptional
repressor LSD1
In search for the co-regulator(s) involved in the S-50-
mediated response to TSA, we resolved electrophoretically
the nuclear proteins retained over S-50-coupled streptavidin-
magnetic beads. The bands marked with dots clearly showed
higher intensity upon TSA treatment (Figure 7a, compare
lanes 1 and 2) and were sensitive to competition with S-50
oligomers (lanes 5, 6). These bands were digested in-gel with
trypsin and subjected to mass spectroscopy. The tryptic
peptide profile for each band was used to identify the
respective proteins through online database search. P1 and
P2 were identified as the polypeptides KIAA0166 and
KIAA0185, respectively (Nagase et al., 1996). They encom-
pass domains characteristic of transcription factors and their
homologs have been found to act as transcriptional co-
regulators (Scaerou et al., 1999; Sweet et al., 2003). P3 and
P5 were identified as nuclear myosin I and b-actin,
respectively. Increased cellular levels of actin have been
previously observed in NHEK in which protein deacetylation
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Figure 7. TSA treatment enhances the recruitment of repressor histone
demethylase LSD1. (a) Coomassie R250-stained SDS protein gel showing the
nuclear proteins from control () and TSA-treated (þ ) NHEK in the bound and
unbound fractions eluted from S-50-coated streptavidin-magnetic beads. The
dots designate the proteins P1–P5, identified by mass spectrometry, whose
retention was diminished upon preincubation of the extracts with excess S-50.
The mobility of the marker proteins (SeeBlue, Invitrogen) is shown on the right.
(b) The amount of LSD1 (top) and total histone H3 (middle) in the input,
bound, and unbound samples described above, as well as in the samples
eluted from streptavidin-magnetic beads, which have not been coated with
DNA (Beads), were estimated by Western blotting. The same samples were
subjected to a demethylation assay and the amount of histone H3 bearing
di-methylated lysine K4 residues was estimated with anti-di-methyl-K4 specific
antibody (bottom). (c) The intensities of LSD1 and di-methyl-K4 in lanes 3–12
were quantitated after scanning and normalized to the intensities of the
respective histone H3 signals. The results are presented as a percentage of the
LSD1/H3 and di-methyl-K4/H3 ratios, respectively, in the control bound
fractions and are derived from three independent experiments.
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has been inhibited by sodium butyrate and may be in part
responsible for the cell shape and motility changes in these
cultures (Staiano-Coico et al., 1989, 1990b) and in the
epidermis (Figure 1h). The association of nuclear myosin and
especially actin and actin-related proteins with chromatin
remodeling, histone acetyl transferase and deacetylase
complexes, and their importance in transcription by RNA
polymerase II has now been firmly established (e.g., see
Blessing et al., 2004). The role these proteins may play in
regulating profilaggrin transcription remains to be investi-
gated.
P4 was identified as KIAA0106. It represents the recently
characterized flavin adenine dinucleotide-dependent histone
demethylase Lysine-Specific Demethylase (LSD1). LSD1
functions as a transcriptional co-repressor by demethylating
lysine 4 (K4) of histone H3, where the methylated status is
associated with active transcription (Shi et al., 2004). The
protein has been found as a component of a number of co-
repressor complexes (Humphrey et al., 2001; Shi et al.,
2005). Perhaps significantly, one of these complexes,
immunoprecipitated with an antibody against HDAC1, also
contained actin (Humphrey et al., 2001).
We confirmed the increased retention of LSD1 over
profilaggrin promoter in response to TSA by probing the
input, bound, and unbound fractions captured over the
promoter with an antibody specific for LSD1 (Figure 7b, top
panel). The amount of histone H3 retained from the respective
samples (middle panel) was used for normalization. Quantita-
tion of the intensities of the scanned bands revealed that the
extract from the TSA-treated NHEK deposited over the
promoter about 3-fold more LSD1 (lanes 5, 6). The difference
reflected the increase in LSD1 in TSA-treated keratinocytes,
detected in the input (lanes 3, 4) and unbound (lanes 7, 8)
samples. Competition with S-50 oligomers (lanes 9, 10)
reduced the retention to only 10% of the control and
eliminated the difference between the TSA-treated and
untreated samples (Figure 7c). To assess the extent to which
the presence of LSD1 correlated with the capacity of the
protein fractions to demethylate lysine K4 of histone H3, bulk
histones were subjected to in vitro demethylation. By using an
antibody specifically recognizing di-methylated lysine K4 of
histone H3 (Figure 7b, lower panel), we observed that the
capacity for demethylation in the TSA-treated samples (lanes
4, 6, and 8) was 2 to 3-fold higher than the respective controls
(lanes 3, 5, and 7). Preincubation of the extracts with S-50 did
not alter this ratio in the unbound fractions (lanes 11, 12) but
increased the amount of di-methyl-K4 remaining in the bound
fractions and eliminated the TSA-induced difference (lanes 9,
10) (see also Figure 7c).
DISCUSSION
Herein, we have provided evidence that when applied at
submicromolar concentrations the class I/II deacetylase
inhibitor TSA causes morphological changes in all layers of
foreskin epidermis. The decreased cellularity and the
disorganization of the basal layer, the reduction in the
number of spinous layers and the thickening of the stratum
corneum are all in agreement with the previously reported
ability of HDACi to induce growth arrest (Brinkmann et al.,
2001), to cause rearrangement of the cytoskeleton (Staiano-
Coico et al., 1989, 1990b) and to promote the formation of
cornified envelopes (Schmidt et al., 1989) in cultured
epidermal keratinocytes. To our knowledge, ours is the first
study examining the effects of altered protein (de)acetylation
on the homeostasis of normal human epidermal tissue.
Recently Chung et al. (2004) reported that topical application
of HDACi, including TSA, after g-irradiation of rat skin leads
to thickening of the epidermis. There are several reasons that
may explain the apparent contradiction between these
observations and our findings. The effect may depend on
the length of the treatment. It may reflect species specificity.
The response to TSA may be influenced by the presence of
hair follicles in the epidermis or by continuous blood supply
through the dermis. The reported rat epidermal hyperplasti-
city may reflect a combined effect of irradiation and HDAC
inhibition.
Our data also illustrate the complexity of the acetylation-
related regulation in the skin cells. As evident from the
chromatin immunoprecipitation experiments, in the dermal
fibroblasts the epidermal genes are buried in transcriptionally
silent hypoacetylated chromatin domains. In NHEK, these
genes reside in hyperacetylated chromatin regions and are
thus open for transcription. However, the transcriptional
competence conferred to the epidermal genes by their
preferential association with acetylated histones is clearly
modulated by downstream acetylation-related events. De-
spite residing in the same chromosome locus, the EDC genes
on 1q21 respond to TSA in a gene-specific rather than cluster-
specific mode. Such gene-specific response differs from the
response of the major histocompatibility class II and the
adjacent histone gene clusters, for example, both of which
are coordinately upregulated upon hyperacetylation in B-
lymphoid cells (Gialitakis et al., 2006). Apparently, the effect
of TSA on the epidermal marker genes is not coordinated with
respect to keratinocyte differentiation either. For the EDC
genes, which are expressed in advanced stages of epidermal
differentiation, superimposed on the transcriptional compe-
tence is the modulation of transcription initiation, which in
the case of profilaggrin is suppressed, in the case of loricrin is
not affected and in the case of involucrin is enhanced.
Whether the normalization of the involucrin levels in the
lower spinous layers of the TSA-treated organ cultures is due
to inhibited transcription initiation in the less differentiated
cells or to post-transcriptional events is at present unclear.
Largely, TSA represses profilaggrin transcription initiation
by inhibiting the promoter activity. The integrity of the Sp1/
Sp3-interacting S-100 and S-50 motifs proximal to the
transcription initiation site is required for the keratinocyte-
specific TSA-mediated repression of the promoter to occur.
As treatment of NHEK with TSA lowers the amounts of Sp1
and Sp3, TSA may be causing repression by simply
diminishing the transactivation provided directly by these
transcription factors. Several of our observations, however,
argue against it being the decisive mechanism. First, the
nuclear extracts derived from TSA-treated cells still contain
significant amounts of Sp1 and Sp3. Second, the effect of TSA
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is sensitive to inhibition of protein synthesis and the nuclear
extracts from TSA-treated keratinocytes are enriched in a
protein(s), which, when added to extracts from untreated
NHEK mimics the TSA effect in vitro. Third, despite the
protein binding similarities between the four profilaggrin S-
motifs (Markova et al., 2006), only S-100 and S-50, which
share a marked homology to the regulatory elements
controlling the response of several genes to the class I/II
HDACi sodium butyrate (see Davie, 2003), represent
profilaggrin TSA-response elements (Figure 3e). Fourth,
treatment of NHEK with TSA not only diminishes the binding
of Sp1(Sp3) at S-100 and S-50 but also enhances interactions,
which result in the recruitment of fewer co-activator histone
acetylases such as CBP and p300 and more co-repressors
such as LSD1 (and possibly actin or actin-related proteins).
The net activity of the Sp1(Sp3) complexes to promote or
hinder transcription depends on the abundance, affinity, and
duration of residence of diverse groups of both DNA-binding
and non-binding proteins on the Sp1(Sp3) multimers (Mas-
trangelo et al., 1991; Davie, 2003). We propose that the
Sp1(Sp3) occupancy at S-100 and S-50 may dictate the
balance between the associated co-activators and co-
repressors. Higher levels of Sp1(Sp3) within the keratinocyte
would ensure that the profilaggrin S-motifs are predominantly
occupied by Sp1(Sp3) and the associated co-activator histone
acetylases CBP and p300. This might contribute to the
formation of a chromatin configuration that favors synergistic
transactivation by c-jun. On the contrary, reduced levels of
Sp1(Sp3) simultaneously with increased synthesis of the
repressive demethylase LSD1 in response to TSA might favor
the assembly of predominantly repressive complexes, which
would replace the acetylase co-activators. The result,
reflected in the appearance of new sites of DNase I
hypersensitivity and reduced binding at the AP1 motif, might
be remodeling of the chromatin into a configuration, which
prevents efficient transactivation of the promoter by c-jun.
To date little is known about the effect of protein
deacetylase inhibition on the expression and activity of
LSD1. Treatment with TSA did not affect the expression of
one LSD1 target gene (SCN2A) in Rat-1 fibroblast cells
(Lunyak et al., 2002) but resulted in derepression of the same
gene in HeLa cells (Shi et al., 2005). Possibly, these
differences reflect species and/or cell specificity. Recently;
Shi et al. (2005) provided evidence that the LSD1 enzyme
may favor hypoacetylated histone substrate. Consistent with
this, the induction of major histocompatibility complex class
II genes by TSA in B-lymphoid cell background involves an
increase in H3 acetylation and lysine K4 methylation
(Gialitakis et al. 2006). The fact that we observed lower
acetylation activity over the profilaggrin promoter tempts us
to speculate that in addition to modulating the acetylation of
specific regulatory proteins (e.g., through diminished CBP/
p300 recruitment), the TSA-mediated reconfiguration may
promote the demethylation of lysine K4 of histone H3 via
local depletion of acetylated histones. This could also be
achieved through activation of TSA-independent class III
deacetylases, which would function upstream of LSD1. At
least one such deacetylase – SIRT1, is recruited over
profilaggrin promoter in an S-motif-dependent mode (Mar-
kova et al., 2006).
Significantly, AP1 and Sp1 interactions have been
determined as critical for the activity of involucrin (Crish
et al., 2006) and loricrin (Jang and Steinert, 2002) promoters,
as well. The differential response of the three EDC genes and
their promoters to TSA in the same cellular milieu suggests
that when deacetylation is inhibited the AP1 and Sp1
transcription factors can assemble distinct combinations of
co-regulators, depending on promoter- and/or DNA-binding
site specificity thus providing an additional level of combi-
natorial control of gene expression. It is also conceivable that
inhibition of deacetylation might promote specific post-
translational modifications of Sp1, AP1, and/or other reg-
ulatory proteins to which the three promoter regions are
differentially sensitive.
Although HDACi invariably cause accumulation of
acetylated histones, only a relatively small number of genes
(2–17%) have been shown so far to change their expression
patterns (Van Lint et al., 1996; Lindemann et al., 2004). The
data presented herein suggest that profilaggrin may be
included in this short list. The disruption of normal epidermal
morphology and the paradoxical downregulation of profilag-
grin expression also suggest that inhibition of protein
deacetylation may cause alterations in the epidermal function
that could lead to skin morbidity and thus pose a challenge to
the clinical applicability of deacetylase inhibitors as either
radiation sensitizers or protectors. Although certainly not
resolving the complexities of the HDACi-mediated regulation
of the epidermal homeostasis, our studies provide a basis for
further investigation, which may facilitate the design of
clinical protocols to maximize the therapeutic effectiveness
and limit the detrimental side effects of HDACi on the
epidermis.
MATERIALS AND METHODS
The committees on research compliance for use of recombinant
DNA and radioactive materials and the ethics committee of the State
University of New York at Stony Brook approved all described
experiments. Parental consent for use of the foreskin samples was
granted. The study was conducted according to the Declaration of
Helsinki Principles.
Plasmids and antibodies
The wild-type and mutant CAT reporters have been described (Jang
et al., 1996). The expression vectors for Sp1, Sp3, and mutant Sp3
were gifts from R. Tjan; the expression vector for c-jun was a gift
from M. Karin. Recombinant Sp1 and c-jun proteins were purchased
from Promega Corp. (Madison, WI). The antibodies against
profilaggrin and loricrin were from Covance (Berkeley, CA); the
anti-involucrin antibody has been described (Simon and Green,
1989). The AlexaFluor-conjugated secondary antibodies were from
Molecular Probes (Eugene, OR). The antibodies against Sp1, Sp3, c-
jun, c-myc, p21, cyclin D and poly(ADP-ribose) polymerase 1, and
the horseradish peroxidase-conjugated secondary antibodies were
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); the
anti-RBP-Jk antibody was from Chemicon (Temecula, CA). The anti-
di-methyl-K4-histone H3 and anti-acetyl-histone H3 antibodies were
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from Upstate Group (Lake Placid, NY). The rabbit anti-LSD1 and
pan-acetyl antibodies were a gift from V. Russanova.
Organ and cell cultures, transfections, and CAT reporter assays
For the organ cultures, fresh neonatal foreskin specimens obtained
from circumcisions were immediately placed in keratinocyte
medium. The medium consists of a 3:1 (v/v) mixture of DMEM
and Ham’s F-12 medium supplemented with adenine (1.8 104 M),
penicillin (1000 U/ml), streptomycin (1 mg/ml), hydrocortisone
(0.4 mg/ml), insulin (5 mg/ml), epidermal growth factor (10 ng/ml),
cholera toxin (1.2 1010 M), CaCl2 (1.2 mM), and 5% fetal bovine
serum (Randolph and Simon, 1993). The samples were incubated
with continuous rotation in the absence or presence of 100 nM TSA
for 48 hours at 371C. NHEK derived from neonatal foreskin were
cultured in the same medium over 3T3 feeder layers as described
(Randolph and Simon, 1993). HeLa cells were purchased from ATCC
(Bethesda, MD) and grown in DMEM according to supplier’s
recommendations. Where indicated, the cells were treated for the
designated periods of time with 100 or 200 nM TSA, 10 mg/ml
cycloheximide, or 5mg/ml actinomycin D. Under the experimental
conditions over 90% of the TSA-treated cells remained viable and
non-apoptotic. The transfections and the measurement of the CAT
activity 48–60-hour post-transfection were carried out as published
by Jang et al. (1996).
Indirect immunofluorescence and Western blot analyses
The indirect immunofluorescence was carried out on frozen sections
of the organ cultures as previously published (Markova et al., 2006).
Western blot analyses were performed with nitrocellulose replicas of
proteins resolved on pre-cast gels (Invitrogen, Carlsbad, CA),
developed with SuperSignal West Pico system (Pierce, Rockford,
IL), detected on Kodak BioMax Light films and quantitated after
scanning with Un-scan-it Gel software (Silk Scientific Co., Orem,
UT). The loading and transfer were monitored by irreversible
staining of the protein gels after transfer with GelCode Blue Stain
Reagent (Pierce, Rockford, IL) and by reversible staining of the
nitrocellulose filters with Ponceau S (Sigma, St Louis, MO).
RNA and nuclear run-on analyses
Total RNA was extracted from heat separated foreskin epidermis
(Steinert et al., 1985) or from NHEK with Trizol (Life Technologies,
Gaithersburg, MD), resolved on methylmercury denaturing gels,
transferred to nitrocellulose and hybridized to the indicated
[a-32P]dCTP-labeled cDNA probes as described previously (Andreoli
et al., 1997). Conventional RNase protection was carried out with
total NHEK RNA and labeled antisense RNA probes using HybSpeed
RPA kit from Ambion (Austin, TX). The protected RNA fragments
were resolved on 6% denaturing polyacrylamide gels (Invitrogen,
Carlsbad, CA) and detected on Kodak BioMax MS or MR films. The
RT-PCR was performed on 0.5 mg total RNA with profilaggrin-
specific primers (0.3 mM) or GAPDH-specific primers (0.06 mM) using
OneStep RT-PCR kit (Qiagen Inc., Valencia, CA). To increase the
sensitivity, 1 mCi [a-33P]dCTP was included in the reactions and the
amplified region of both mRNAs was shorter than 200 nt. The
labeled cDNA fragments were resolved on 6% denaturing DNA gels
and detected on Kodak BioMax MR films. Nuclei were isolated from
cultured NHEK as described by Dlugosz and Yuspa (1993). The
in-vitro elongation of the initiated transcripts and their detection by
hybridization with specific cDNA fragments was performed as
previously published (Jang et al., 1996). For the RNase H protection,
the labeled nascent transcripts were hybridized to biotinylated
antisense oligonucleotides corresponding to the first 64 bases of
profilaggrin or GAPDH mRNA. The duplexes were captured on
streptavidin-magnetic beads and digested with RNase H as described
by Russanova et al. (1995). The protected RNA fragments were
eluted from the beads, resolved, and detected as for the conventional
RNase protection. The relative intensities of the signals obtained in
the RNA analyses were quantitated after scanning of the films using
Un-scan-it Gel software.
Chromatin immunoprecipitation
The chromatin immunoprecipitation experiments were carried out as
described by Markova et al. (2006). The in vivo crosslinked
chromatin was incubated overnight with 50 mg rabbit anti pan-
acetyl antibody or nonspecific IgGs, followed by an overnight
incubation with magnetic beads-coupled anti-rabbit IgG. The bound
material was eluted, the crosslinks were reversed and the immuno-
precipitated DNA was amplified by PCR with primers specific for
profilaggrin, involucrin, loricrin, and GAPDH genes. The PCR
fragments were resolved electrophoretically and detected on Kodak
BioMax MR films. The histone proteins were precipitated according
to Lennox and Cohen (1989) and analyzed by Western blotting.
Preparation of nuclear extracts, bandshift, and DNase I
footprinting analysis
The NHEK nuclear extracts were prepared and assayed in bandshift
experiments as described previously (Jang et al., 1996; Markova
et al., 2006). The sequences of all oligonucleotides are available
upon request. The DNase I footprinting of the profilaggrin promoter
fragment 147/þ 9 was carried out with SureTrack DNase I
footprinting system (Pharmacia Biotech, Uppsala, Sweden) as
suggested by the manufacturer.
Promoter-capture, acetyl transferase, and demethylation assays
Biotinylated profilaggrin promoter fragment 147/þ 9 or double-
stranded S-50 oligonucleotides (2–4 pmoles) were captured over
200mg M-280 streptavidin-magnetic beads (Dynal, Carlsbad, CA) in
10 mM Tris, pH 8.0, 1 mM EDTA. The unconjugated DNA (less than
90%) was removed with a magnetic particle concentrator. The DNA-
conjugated beads were blocked by 0.5% BSA in TGED buffer (20 mM
HEPES, pH 7.9, 1 mM EDTA, 10% glycerol, 0.01% Triton X100,
10 mM sodium butyrate) and then incubated overnight at 41C with
500mg NHEK nuclear extracts in the same buffer supplemented with
100 mM NaCl. The beads were extensively washed with TGED buffer
and the specifically bound proteins were eluted in 30 ml TGED buffer
supplemented with 1 M NaCl (Masumi et al., 1999). The acetylation
activity of the input, unbound and bound samples was assessed with
1mg unfractionated bulk histones (Sigma-Aldrich, St Louis, MO) and
[H3]-coenzyme A, as described by Markova et al. (2006). The
demethylation assay with the same samples was carried out with
30 mg unfractionated bulk histones in demethylation buffer, accord-
ing to Shi et al. (2004), after desalting of the protein samples.
Identification of TSA-induced S-50-captured proteins
Proteins captured over S-50-coated streptavidin-magnetic beads
were separated on SDS gels and identified as described by Marekov
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and Steinert (2003). Mass spectra were acquired on a Voyager DE-
Pro time-of-flight mass spectrometer. Proteins were identified by an
online database search (http://129.85.19.192/profound_bin/Web-
ProFound.exe).
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